Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease

This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease.

Detalles Bibliográficos
Autores principales: Zissimopoulos, Julie, Jacobson, Mireille, Chen, Yi, Borson, Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845005/
https://www.ncbi.nlm.nih.gov/pubmed/35157058
http://dx.doi.org/10.1001/jamanetworkopen.2021.48355
Descripción
Sumario:This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease.

Ejemplares similares